Payment overview · 2025
General Payments
$188.77
10 reported records · 6 companies
Healthcare provider profile · identity verified
Hamza Ismail, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · IOWA CITY, IA · NPI 1962693903
Verified facts
What the public records show
CMS Open Payments records show Hamza Ismail, M.D. received $188.77 in general payments during 2025 across 10 reported records.
Novo Nordisk Inc accounted for 29.6% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Ozempic, Rybelsus.
E.R. Squibb & Sons, L.L.C. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 27956 records involving 14870 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Eliquis by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 43 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 138 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $55.80 | 29.6% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $43.32 | 22.9% | 2 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $41.37 | 21.9% | 2 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $18.14 | 9.6% | 1 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $15.97 | 8.5% | 1 | 2025 |
| E.R. Squibb & Sons, L.L.C. | Unresolved — no canonical attribution shown | $14.17 | 7.5% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $188.77 | 10 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $43.32 | 2 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $40.46 | 2 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $22.41 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $18.96 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $18.14 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN Access System Normalized: watchman access system |
Device | Boston Scientific Corporation | $15.97 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| Rybelsus Normalized: rybelsus |
Drug | Novo Nordisk Inc | $15.34 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | E.R. Squibb & Sons, L.L.C. | $14.17 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 138 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| Rybelsus rybelsus |
2025 | Rybelsus | 2024 | 43 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 27956 supporting records · 14870 recipient NPIs · example record 1184377713 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
138 | 19 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
43 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
138 | 19 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
22 | 22 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 699 | 185 |
| Levothyroxine Sodium | Levothyroxine Sodium | 624 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 536 | 127 |
| Losartan Potassium | Losartan Potassium | 467 | 103 |
| Amlodipine Besylate | Amlodipine Besylate | 423 | 108 |
| Jardiance | Empagliflozin | 372 | 82 |
| Omeprazole | Omeprazole | 363 | 88 |
| Duloxetine Hcl | Duloxetine Hcl | 330 | 69 |
| Metoprolol Succinate | Metoprolol Succinate | 305 | 66 |
| Tamsulosin Hcl | Tamsulosin Hcl | 293 | 74 |
| Lisinopril | Lisinopril | 278 | 65 |
| Furosemide | Furosemide | 271 | 58 |
| Potassium Chloride | Potassium Chloride | 256 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 234 | 63 |
| Metformin Hcl | Metformin Hcl | 230 | 55 |
| Pantoprazole Sodium | Pantoprazole Sodium | 226 | 60 |
| Alendronate Sodium | Alendronate Sodium | 222 | 49 |
| Simvastatin | Simvastatin | 196 | 40 |
| Gabapentin | Gabapentin | 191 | 37 |
| Montelukast Sodium | Montelukast Sodium | 177 | 34 |
| Allopurinol | Allopurinol | 156 | 33 |
| Donepezil Hcl | Donepezil Hcl | 149 | 26 |
| Ezetimibe | Ezetimibe | 148 | 42 |
| Pravastatin Sodium | Pravastatin Sodium | 146 | 32 |
| Clopidogrel | Clopidogrel Bisulfate | 144 | 21 |
| Metformin Hcl Er | Metformin Hcl | 139 | 42 |
| Eliquis | Apixaban | 138 | 19 |
| Alprazolam | Alprazolam | 111 | 30 |
| Sertraline Hcl | Sertraline Hcl | 106 | 31 |
| Tramadol Hcl | Tramadol Hcl | 106 | 32 |
| Meloxicam | Meloxicam | 100 | 35 |
| Escitalopram Oxalate | Escitalopram Oxalate | 97 | 19 |
| Clonazepam | Clonazepam | 92 | 13 |
| Glipizide Er | Glipizide | 88 | 23 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 77 | 14 |
| Carvedilol | Carvedilol | 77 | 23 |
| Metoprolol Tartrate | Metoprolol Tartrate | 76 | 17 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 75 | 23 |
| Mounjaro | Tirzepatide | 75 | 17 |
| Trazodone Hcl | Trazodone Hcl | 74 | 18 |
| Warfarin Sodium | Warfarin Sodium | 73 | 15 |
| Bupropion Xl | Bupropion Hcl | 72 | 14 |
| Doxazosin Mesylate | Doxazosin Mesylate | 72 | 19 |
| Quetiapine Fumarate | Quetiapine Fumarate | 72 | 12 |
| Spironolactone | Spironolactone | 70 | 18 |
| Zolpidem Tartrate | Zolpidem Tartrate | 68 | 17 |
| Fluticasone Propionate | Fluticasone Propionate | 66 | 20 |
| Lorazepam | Lorazepam | 65 | 17 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 65 | suppressed |
| Levetiracetam | Levetiracetam | 60 | 11 |
| Finasteride | Finasteride | 59 | 13 |
| Mirtazapine | Mirtazapine | 58 | suppressed |
| Topiramate | Topiramate | 56 | 14 |
| Xarelto | Rivaroxaban | 56 | 13 |
| Atenolol | Atenolol | 55 | 13 |
| Glimepiride | Glimepiride | 54 | 14 |
| Hydralazine Hcl | Hydralazine Hcl | 53 | 11 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 53 | 33 |
| Pregabalin | Pregabalin | 53 | 13 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 52 | 15 |
| Amoxicillin | Amoxicillin | 50 | 19 |
| Myrbetriq | Mirabegron | 49 | suppressed |
| Prednisone | Prednisone | 49 | 24 |
| Torsemide | Torsemide | 49 | 13 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 48 | 21 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 48 | 13 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 47 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 45 | 12 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 44 | 13 |
| Rybelsus | Semaglutide | 43 | suppressed |
| Valsartan | Valsartan | 43 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 41 | suppressed |
| Tresiba Flextouch U-100 | Insulin Degludec | 40 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 40 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 39 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 37 | suppressed |
| Synthroid | Levothyroxine Sodium | 37 | suppressed |
| Azithromycin | Azithromycin | 36 | 29 |
| Paroxetine Hcl | Paroxetine Hcl | 36 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 35 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 33 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 32 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 31 | suppressed |
| Estradiol | Estradiol | 31 | 12 |
| Fenofibrate | Fenofibrate | 31 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 30 | 11 |
| Symbicort | Budesonide/Formoterol Fumarate | 29 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 27 | 23 |
| Colestipol Hcl | Colestipol Hcl | 26 | suppressed |
| Ketoconazole | Ketoconazole | 26 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 26 | suppressed |
| Trulicity | Dulaglutide | 26 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 25 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 25 | suppressed |
| Levofloxacin | Levofloxacin | 25 | 20 |
| Linzess | Linaclotide | 25 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 25 | suppressed |
| Chlorthalidone | Chlorthalidone | 24 | suppressed |
| Autoshield Duo Pen Needle | Pen Needle,dual Safety,diabetc | 23 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 23 | suppressed |
| Farxiga | Dapagliflozin Propanediol | 23 | suppressed |
| Ibandronate Sodium | Ibandronate Sodium | 23 | suppressed |
| Irbesartan | Irbesartan | 23 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 22 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 22 | 22 |
| Celecoxib | Celecoxib | 21 | suppressed |
| Famotidine | Famotidine | 21 | suppressed |
| Fluconazole | Fluconazole | 21 | 15 |
| Novolog Flexpen | Insulin Aspart | 21 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 21 | suppressed |
| Ramipril | Ramipril | 20 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 18 | suppressed |
| Divalproex Sodium Er | Divalproex Sodium | 18 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 17 | 15 |
| Donepezil Hcl Odt | Donepezil Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 16 | suppressed |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 16 | suppressed |
| Lamotrigine | Lamotrigine | 16 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 16 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 16 | suppressed |
| Sucralfate | Sucralfate | 16 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 16 | suppressed |
| Diazepam | Diazepam | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 15 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 15 | suppressed |
| Ranolazine Er | Ranolazine | 15 | suppressed |
| Rexulti | Brexpiprazole | 15 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 15 | suppressed |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 15 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 14 | suppressed |
| Felodipine Er | Felodipine | 14 | suppressed |
| Glipizide | Glipizide | 14 | suppressed |
| Klor-Con M20 | Potassium Chloride | 14 | suppressed |
| Loperamide | Loperamide Hcl | 14 | suppressed |
| Savella | Milnacipran Hcl | 14 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 14 | suppressed |
| Tramadol Hcl-Acetaminophen | Tramadol Hcl/Acetaminophen | 14 | suppressed |
| Trandolapril | Trandolapril | 14 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 14 | suppressed |
| Budesonide Ec | Budesonide | 13 | suppressed |
| Carbidopa-Levodopa Er | Carbidopa/Levodopa | 13 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 13 | suppressed |
| Dutasteride | Dutasteride | 13 | suppressed |
| Entresto | Sacubitril/Valsartan | 13 | suppressed |
| Gemtesa | Vibegron | 13 | suppressed |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 12 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 12 | suppressed |
| Januvia | Sitagliptin Phosphate | 12 | suppressed |
| Methocarbamol | Methocarbamol | 12 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 11 | suppressed |
| Latanoprost | Latanoprost | 11 | suppressed |
| Novolog Mix 70-30 Flexpen | Insulin Aspart Prot/Insuln Asp | 11 | suppressed |
| Ozempic | Semaglutide | 11 | suppressed |
| Sulfasalazine | Sulfasalazine | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $188.77 · 10 records | Novo Nordisk Inc | ABRYSVO, COMIRNATY, ELIQUIS, FREESTYLE LIBRE 3, NURTEC ODT, Ozempic, PREVNAR 20, Rybelsus, TZIELD, WATCHMAN Access System, Wegovy, ZAVZPRET | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with E.R. Squibb & Sons, L.L.C.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error